Atlas Trials

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Clinical trial NCT03876769 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03876769
Sponsor
Novartis Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
B-Cell Acute Lymphoblastic Leukemia
Start date
2019-06-24
Primary completion
2027-10-19
Enrollment
121

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.